CADISTA HOLDINGS INC BALANCE SHEET

Size: px

Start display at page:

Download "CADISTA HOLDINGS INC BALANCE SHEET"

Theodore Beasley
5 years ago
Views:

1 BALANCE SHEET As at 31 March, I. EQUITY AND LIABILITIES Shareholders' Funds Share capital Reserves and surplus Current liabilities Note No. l ,797 5, ,797 5,399 33,501,432 2,008,728 33,513,767 1,820,459 33,619,229 2,014,127 33,631,564 1,825,858 Other current liabilities 3 66,087 3,959 66,087 3,588 66,087 3,959 66,087 3,588 II. ASSETS Non current assets Non current investments Long term loans and advances Total ,685,316 2,018,086 33,697,651 1,829, ,617,771 2,014,039 33,630,144 1,825,781 Current assets Cash and bank balances 6 33,617,772 2,014,039 33,630,145 1,825,781 Total 33,685,316 2,018,086 33,697,651 1,829,446 RAJNEESH GUPTA HEAD ACCOUNTS Place : Noida Date : 22 May 2014

2 STATEMENT OF PROFIT AND LOSS For the year ended 31 March, Note No USD 2013 Rs. '000 USD Rs. '000 REVENUE Other Non Operating Income Other income Total revenue EXPENSES Other expenses Total expenses 8 12,374 12, , , loss before tax Tax expenses: loss after tax Current tax MAT credit entitlement Deferred tax charge/( credit) (12,336) (12,336) (742) (12,390) (673) (742) (12,390) (673) RAJNEESH GUPTA HEAD ACCOUNTS Place : Noida Date : 22 May 2014

3 . Cash flow statement for the year ended 31 March, Particulars Cash flows from operating activities Loss before tax (12,336) (742) (12,390) (673) Adjustments : Interest income (38) {2) {107) {6) (38) (2) (107) (6) Operating profit before working capital changes (12,374) (744) (12,497) (679) Adjustments for : (lncrease)/decrease in trade and other receivables 12, , B. Cash flow arising from investing activities : Interest received Net cash inflow/(outflow) in course of investing activities C. Foreign currency translation difference arising on consolidation Net Increase in cash and cash equivalents (A+B+C) Add: cash and cash equivalents at the beginning of year 67,506 3,665 67,399 3,429 Cash and cash equivalents at the close of the year RAJNEESH GUPTA HEAD ACCOUNTS Place: Noida Date : 22 May 2014

4 As at 31 March, 1. SHARE CAPITAL Authorized 120,000,000 Equity shares of USD per share (Previous Year 120,000,000 Equity shares of USD per share) 2014 USD 120, , Rs. '000 USD Rs. ' , ,000. Issued, Subscribed & Paid Up 117,797,180 Equity shares of USD per share (Previous Year 117,797,180 Equity shares of USD per share) 117, ,797 5, ,797 5,399 5, ,797 5, ) The Company has only one class of common stock having a par value of USD per share. Each holder of common stock is entitled to one vote per share. 1.2) In the event of liquidation of the Company, the holders of common stock shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of shares held by the common stockholders. 1.3) During the year , company bought back 100,000 shares from one of the shareholder. 1.4) The details of shares held by holding/ultimate holding company and /or their subsidiaries/associates: 31 March,14 31 March,13 Name ofthe company Generic Pharmaceuticals Holdings Inc., USA the holding company 97,043,574 97,044 97,043,574 97,044 Equity shares of USD per share fully paid 1.5) The details of shareholders holding more than 5% shares in the company: 31 March,14 31 March,13 Name of the shareholder No. of shares %holding No. of shares %holding Generic Pharmaceuticals Holdings Inc., USA the holding company 97,043, % 97,043, % 1.6) The reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period. 31 March, March,13 Name of the shareholder No. of shares Amount No. of shares Amount Number of shares at the beginning and at the end ofthe year 117,797,180 5, ,797,180 5,399

5 As at 31 March, RESERVES AND SURPLUS Securities premium account Balance at the beginning and at the end of the year 38,755,539 1,770,348 38,755,539 1,770,348 38,755,539 1,770,348 38,755,539 1,770,348 Foreign currency translation reserve Opening balance 284, ,296 Addition during the year 189, , , ,191 Surplus as per Statement of Profit and Loass As per last Balance Sheet (5,241,771) (234,080) (5,229,382) (233,407) Add: Net loss after tax transferred from Statement of Profit and loss (12,336) (742) (12,390) (673) Amount available for appropriation (5,254,107) (234,822) (5,241,772) (234,080) (5,254,107) (234,822) (5,241,712) (234,080) 33,501,432 2,008,728 33,513,767 1,820,459

6 As at 31 March, OTHER CURRENT LIABILITIES Unpaid dividends 66,087 3,959 66,087 3,588 66,087 3,959 66,087 3, NON CURRENT INVESTMENTS (At Cost) Trade Investments Investment in Equity Instruments (Fully Paid up Equity Shares) Investment in Subsidiary Company: Jubilant Cadista Pharmaceuticals Inc. USA Share (Previous year: 1 Share) of USD 1 each LONG TERM LOANS AND ADVANCES loans to related parties( unsecured considered good) 33,617,771 2,014,039 33,630,144 1,825,781 Jubilant Cadista Pharmaceuticals Inc. (non interest bearing) 33,617,771 2,014,039 33,630,144 1,825, CASH AND BANK BALANCES Cash and cash equivalents Balances with banks: On current accounts

7 For the year ended 31 March, OTHER INCOME Other nonoperating income Interest Income OTHER EXPENSES Rates and taxes 12, , , ,

JUBilANT DRAXIMAGE {USA) INC

JUBilANT DRAXIMAGE {USA) INC Balance Sheet As at 31st March, I. EQUITY AND liabilities Shareholders' Funds Share Capital Reserves & Surplus Note No 1 2 2014 2013 USD ~in OOO's USD ~in OOO's 9 0 9 0 (1,11,676)